16.11.2019 – 21:38
Montreal, 30 April / PRNewswire / –
– Montreal Heart Institute (MHI) today announced the results of its study of the COLchicine Cardiovascular Outcomes Trial (COLCOT). This important study compares the effects of colchicine in the prevention of ischemic cardiovascular disease in patients with recent myocardial infarction (MI) who receive standard care. In this study, patients who received 0.5 mg of colchicine every day in addition to standard treatment had lower first and recurrent ischemic cardiovascular disease rates compared to patients who received standard treatment alone. These data are simultaneously on New England Journal of Medicine (NEJM) and presented today at the American Heart Association (AHA) Scientific Session.
Pharmascience Inc. is proud to have contributed to this innovative clinical trial, the results of which can have a significant positive impact on patient cardiovascular outcomes and public health in general. Inflammation in cardiovascular disease has been shown to play an important role and COLCOT results show very significant progress in linking the reduction of inflammation after myocardial infarction with an increase in cardiovascular outcome.
An important aspect of the COLCOT study is the possible use of new colchicine, a drug that has been used for decades to treat gout and familial Mediterranean fever. New uses for older, more established drugs involve finding additional uses for approved drugs.
"Pharmascience has chosen to support innovations in medical care, such as COLCOT here in Canada, with the aim of promoting therapeutic innovations and improving patient outcomes with new indications for proven and old drugs that can be given affordably." David Goodman, CEO of Farmascience. "We believe these projects are well suited to our desire to contribute to the progress of therapy through responsible entrepreneurship."
The clinical use of colchicine is supported by the fact that its safety profile is well known and very affordable compared to some newer cardiovascular drugs for similar indications. New generic drugs are an attractive and cost-effective choice for public and private drug replacement programs in the context of ongoing problems with the affordability of new drugs.
"Unfortunately, only a few pharmaceutical companies follow this path, because there are inherent economic obstacles," Dr. Goodman "There is no guarantee that additional research and development costs associated with the new use of drugs will return because generic drugs do not protect intellectual property." Farmascience is ready to take that risk for the benefit of the community. But they need the help of the authorities and drug program managers for approval and replacement, which does not slow down new uses, but instead replaces innovation. "
INFORMATION ABOUT PHARMASCIENCE INC.
Founded in 1983, Pharmascience Inc. is the largest pharmaceutical manufacturing company in Qebec with 1,500 employees and headquarters in Montreal. Pharmascience Inc. is a private pharmaceutical company that offers a variety of services and is rooted in Canada. With sales in more than 60 countries, global presence is growing. Utilizing more than $ 43 million in 2018, Pharmascience Inc. ranked 56th among 100 Canadian R&D investors and is the fourth largest generic drug producer in the country.
Pharmascience Inc. has strong values based on the importance of investing in people and young people. The company provides personal and life development through various programs and initiatives. In 2019, Pharmascience Inc. was recognized for its investment by being selected as one of Canada's Top Young Entrepreneurs by Canada's Top 100 Entrepreneur Project and named one of the best companies in Montreal. In 2018, the prestigious magazine Forbes Pharmascience Inc. ranked among the 300 best companies.
Andrea Frascione, Manager, Communication, Tel .: 514-796-4067
Original Content by: Pharmascience Inc., transmitted by actuell news